Eisai Newsroom http://eisai.mediaroom.com/ Eisai Newsroom Independent Imaging Review Confirmed Positive Data from Primary Analysis of REFLECT Trial Evaluating Lenvatinib Compared to Sorafenib in Unresectable Hepatocellular Carcinoma http://eisai.mediaroom.com/2018-01-19-Independent-Imaging-Review-Confirmed-Positive-Data-from-Primary-Analysis-of-REFLECT-Trial-Evaluating-Lenvatinib-Compared-to-Sorafenib-in-Unresectable-Hepatocellular-Carcinoma - Results of tumor response assessments by blinded independent imaging review using both mRECIST and RECIST v1.1 criteria to be presented today at the Gastrointestinal Cancers Symposium Fri, 19 Jan 2018 08:08:00 -0500 http://eisai.mediaroom.com/2018-01-19-Independent-Imaging-Review-Confirmed-Positive-Data-from-Primary-Analysis-of-REFLECT-Trial-Evaluating-Lenvatinib-Compared-to-Sorafenib-in-Unresectable-Hepatocellular-Carcinoma Eisai and Merck Receive Breakthrough Therapy Designation from FDA for LENVIMA® (lenvatinib mesylate) and KEYTRUDA® (pembrolizumab) as Combination Therapy for Advanced and/or Metastatic Renal Cell Carcinoma http://eisai.mediaroom.com/2018-01-09-Eisai-and-Merck-Receive-Breakthrough-Therapy-Designation-from-FDA-for-LENVIMA-R-lenvatinib-mesylate-and-KEYTRUDA-R-pembrolizumab-as-Combination-Therapy-for-Advanced-and-or-Metastatic-Renal-Cell-Carcinoma Tue, 09 Jan 2018 06:45:00 -0500 http://eisai.mediaroom.com/2018-01-09-Eisai-and-Merck-Receive-Breakthrough-Therapy-Designation-from-FDA-for-LENVIMA-R-lenvatinib-mesylate-and-KEYTRUDA-R-pembrolizumab-as-Combination-Therapy-for-Advanced-and-or-Metastatic-Renal-Cell-Carcinoma Encouraging Updated Results from Phase 1b/2 Study Evaluating the Combination of Eribulin Mesylate and Pembrolizumab in Patients with Metastatic Triple-Negative Breast Cancer Presented at the 2017 SABCS http://eisai.mediaroom.com/2017-12-08-Encouraging-Updated-Results-from-Phase-1b-2-Study-Evaluating-the-Combination-of-Eribulin-Mesylate-and-Pembrolizumab-in-Patients-with-Metastatic-Triple-Negative-Breast-Cancer-Presented-at-the-2017-SABCS - Results of this combination study were presented in a Spotlight Session (Spotlight Session 6: PD6-13) on December 7 Fri, 08 Dec 2017 08:08:00 -0500 http://eisai.mediaroom.com/2017-12-08-Encouraging-Updated-Results-from-Phase-1b-2-Study-Evaluating-the-Combination-of-Eribulin-Mesylate-and-Pembrolizumab-in-Patients-with-Metastatic-Triple-Negative-Breast-Cancer-Presented-at-the-2017-SABCS Eisai presentations at the Annual Meeting of the American Epilepsy Society (AES) included key data on long-term convulsive seizure-freedom rates of adjunctive perampanel (marketed as FYCOMPA® CIII) in adolescent patients, monotherapy in partial-onset seiz http://eisai.mediaroom.com/2017-12-06-Eisai-presentations-at-the-Annual-Meeting-of-the-American-Epilepsy-Society-AES-included-key-data-on-long-term-convulsive-seizure-freedom-rates-of-adjunctive-perampanel-marketed-as-FYCOMPA-R-CIII-in-adolescent-patients-monotherapy-in-partial-ons - About 31% of patients with secondarily generalized (SG) and 50% of those with primarily generalized tonic-clonic (PGTC) seizures experienced convulsive seizure-freedom at year three in open-label extension study in adolescents Wed, 06 Dec 2017 16:21:00 -0500 http://eisai.mediaroom.com/2017-12-06-Eisai-presentations-at-the-Annual-Meeting-of-the-American-Epilepsy-Society-AES-included-key-data-on-long-term-convulsive-seizure-freedom-rates-of-adjunctive-perampanel-marketed-as-FYCOMPA-R-CIII-in-adolescent-patients-monotherapy-in-partial-ons Child Neurology Foundation and Eisai Announce New Transitions of Care Resources for Young People Living with Epilepsy http://eisai.mediaroom.com/2017-12-05-Child-Neurology-Foundation-and-Eisai-Announce-New-Transitions-of-Care-Resources-for-Young-People-Living-with-Epilepsy Tools now available to help adolescents with epilepsy transition to the adult health care system underscoring Eisai's leadership and commitment to the epilepsy community Tue, 05 Dec 2017 13:28:00 -0500 http://eisai.mediaroom.com/2017-12-05-Child-Neurology-Foundation-and-Eisai-Announce-New-Transitions-of-Care-Resources-for-Young-People-Living-with-Epilepsy